Sign in Subscribe
Pharmaceutical industry

Global Liver Cancer Drugs Market Analysis

Strategic Insights

— 1 min read

The global liver cancer market is a rapidly growing segment, with a projected annual revenue of $1.3 billion by 2015, growing at a CAGR of 14.9% from 2007 to 2015. The market is predominantly driven by the increasing prevalence and incidence of liver cancer, particularly in Asia. Nexavar, a targeted therapy, is the only approved treatment for liver cancer and has been successful in clinical trials. Several new pipeline drugs, including ThermoDox and sorafenib, are also being developed to treat liver cancer.

Key Takeaways:

  • The global liver cancer market is expected to reach $1.3 billion by 2015, growing at a CAGR of 14.9% from 2007 to 2015.
  • Nexavar is the only approved targeted therapy for liver cancer, with sales of $1.1 billion in 2010.
  • ThermoDox, a new pipeline drug, is expected to enter the market in 2011 and has the potential to significantly impact the treatment of liver cancer.
  • Several new drugs are in various stages of clinical trials, including sorafenib, avastin, and tarceva.
  • The market is driven primarily by the increasing prevalence and incidence of liver cancer, particularly in Asia.
  • The majority of patients are diagnosed with liver cancer at an advanced stage, making treatment more challenging.
  • Targeted therapies are becoming increasingly effective in treating liver cancer, with Nexavar being the only approved treatment.

Statistics:

  • The global liver cancer market is expected to grow at a CAGR of 14.9% from 2007 to 2015.
  • Nexavar sales are expected to reach $1.5 billion by 2015.
  • ThermoDox sales are expected to reach $2.5 billion by 2015.
  • The prevalence of liver cancer is highest in Asia, particularly in China, Japan, and India.
  • The incidence of liver cancer is increasing in the US, with an estimated 28,600 new cases in 2010.
  • Targeted therapies have shown significant promise in treating liver cancer, with a response rate of 30% in Phase III clinical trials.

Sources:

  • Reportlinker.com, Global Liver Cancer Drugs market report, 2011
  • 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann-La Roche Ltd., Jennerex Biotherapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd.

Read more